In solid tumors, including colorectal, lung and pancreatic cancer, KRAS is mutated much more frequently than NRAS; the reverse is true in some hematologic cancers such as acute lymphoblastic and chronic myelomonocytic leukemias, and Hodgkin lymphoma [5], (Table 3). This evidence concerns the gene KRAS and familial pancreatic carcinoma.